Quick Answer
TScan Therapeutics, Inc. reported Total Assets of $228.79 million for the year ending 2025.
- TScan Therapeutics, Inc. showed a decrease of -38.4% in Total Assets from 2024 to 2025.
- This data is from TScan Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $130.01 million | Q3 2021: $204.89 million | Q1 2022: $168.20 million | Q2 2022: $152.42 million | Q3 2022: $165.45 million | Q1 2023: $173.58 million | Q2 2023: $316.92 million | Q3 2023: $291.38 million | Q1 2024: $240.83 million | Q2 2024: $374.87 million | Q3 2024: $348.03 million | Q1 2025: $332.71 million | Q2 2025: $298.56 million | Q3 2025: $262.23 million.
- Over the full 6 years of available data (2020 to 2025), TScan Therapeutics, Inc.'s Total Assets has grown by 360.0%.
- Historical annual values: Fiscal year 2025: $228.79 million | Fiscal year 2024: $371.12 million | Fiscal year 2023: $272.15 million | Fiscal year 2022: $199.09 million | Fiscal year 2021: $188.11 million | Fiscal year 2020: $49.74 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: